Literature DB >> 5158835

Factors influencing the prognosis in myelomatosis.

A A Dawson, D Ogston.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 5158835      PMCID： PMC2467330          DOI： 10.1136/pgmj.47.552.635

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


× No keyword cloud information.
  10 in total

1.  Myelomatosis.

Authors:  J INNES; J NEWALL
Journal:  Lancet       Date:  1961-02-04       Impact factor: 79.321

2.  The incidence of myelomatosis.

Authors:  N H MARTIN
Journal:  Lancet       Date:  1961-02-04       Impact factor: 79.321

3.  Duration of survival in multiple myeloma.

Authors:  M FEINLEIB; B MACMAHON
Journal:  J Natl Cancer Inst       Date:  1960-06       Impact factor: 13.506

4.  Prognosis in eighty cases of multiple myeloma.

Authors:  H JOHANSEN; A VIDEBAEK
Journal:  Dan Med Bull       Date:  1956-09

5.  Cyclophosphamide vs melphalan in treatment of plasma cell myeloma.

Authors:  S L Rivers; M E Patno
Journal:  JAMA       Date:  1969-02-17       Impact factor: 56.272

6.  Growth rates and responses to treatment in human myelomatosis.

Authors:  J R Hobbs
Journal:  Br J Haematol       Date:  1969-06       Impact factor: 6.998

Review 7.  The treatment of plasma cell myeloma.

Authors:  D E Bergsagel; K M Griffith; A Haut; W J Stuckey
Journal:  Adv Cancer Res       Date:  1967       Impact factor: 6.242

8.  A progress report on the Medical Research Council's therapeutic trial in myelomatosis.

Authors:  D A Galton; R Peto
Journal:  Br J Haematol       Date:  1968-09       Impact factor: 6.998

9.  The management of myelomatosis.

Authors:  A F Broad; J N Godlee; E W Emery; T A Prankerd
Journal:  Postgrad Med J       Date:  1968-10       Impact factor: 2.401

10.  Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens.

Authors:  R Alexanian; A Haut; A U Khan; M Lane; E M McKelvey; P J Migliore; W J Stuckey; H E Wilson
Journal:  JAMA       Date:  1969-06-02       Impact factor: 56.272
  10 in total
  7 in total

Review 1.  Novel approaches for reducing free light chains in patients with myeloma kidney.

Authors:  Colin A Hutchison; Joan Bladé; Paul Cockwell; Mark Cook; Mark Drayson; Jean-Paul Fermand; Efstathios Kastritis; Robert Kyle; Nelson Leung; Sonia Pasquali; Christopher Winearls
Journal:  Nat Rev Nephrol       Date:  2012-02-21       Impact factor: 28.314

2.  Maintenance hemodialysis in myeloma kidney disease.

Authors:  N D Vaziri; R Goldman; R G Schultze; D B Lee; S M Rosen
Journal:  West J Med       Date:  1977-02

3.  Efficacy of the M-2 protocol in previously untreated patients with advanced multiple myeloma.

Authors:  H Gössinger; P Bettelheim; E Neumann; W Hinterberger; K Korninger; H Niessner; I Pabinger-Fasching; K Bauer; K Lechner
Journal:  Blut       Date:  1984-11

Review 4.  Current Trends of Renal Impairment in Multiple Myeloma.

Authors:  Punit Yadav; Mark Cook; Paul Cockwell
Journal:  Kidney Dis (Basel)       Date:  2016-02-03

5.  [Analysis of prognostic factors in plasmacytoma].

Authors:  W Gassmann; T Haferlach; N Schmitz; W Kayser; H H Euler; J Drews; H Löffler
Journal:  Klin Wochenschr       Date:  1984-10-01

6.  Treatment of acute renal failure due to myeloma kidney.

Authors:  R A Bear; E H Cole; A Lang; M Johnson
Journal:  Can Med Assoc J       Date:  1980-10-18       Impact factor: 8.262

7.  Iron deficient erythropoiesis might play key role in development of anemia in cancer patients.

Authors:  Silvia Park; Chul Won Jung; Kihyun Kim; Seok Jin Kim; Won Seog Kim; Jun Ho Jang
Journal:  Oncotarget       Date:  2015-12-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.